{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:09:03Z","timestamp":1772827743875,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on\u2010the\u2010road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eligible participants were aged 21\u201375 years with OSA and EDS (Maintenance of Wakefulness Test mean sleep latency &lt;30 minutes and Epworth Sleepiness Scale score \u226510). Participants were randomised 1:1 to solriamfetol (150 mg\/day [3 days], then 300 mg\/day [4 days]) or placebo for 7 days, before crossover to the other treatment paradigm. On Day 7 of each period, standardised on\u2010road driving tests occurred (2 and 6 hours postdose). Standard deviation of lateral position (SDLP) was the primary endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Solriamfetol significantly reduced SDLP at 2 (<jats:italic>n<\/jats:italic> = 34; least squares mean difference, \u20131.1 cm; 95% CI, \u20131.85, \u20130.32; <jats:italic>p<\/jats:italic> = 0.006) and 6 hours postdose (<jats:italic>n<\/jats:italic> = 32; least squares mean difference, \u20130.8 cm; 95% CI, \u20131.58, \u20130.03; <jats:italic>p<\/jats:italic> = 0.043). Two hours postdose, 4 placebo\u2010treated and 1 solriamfetol\u2010treated participants had incomplete driving tests; 6 hours postdose, 7 and 3 participants, respectively, had incomplete tests. Common treatment\u2010emergent adverse events included headache, nausea, and insomnia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Solriamfetol 300 mg\/day significantly improved on\u2010the\u2010road driving performance in participants with EDS associated with OSA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2845","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:14:02Z","timestamp":1653736442000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of solriamfetol on on\u2010the\u2010road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-7742","authenticated-orcid":false,"given":"Frederick","family":"Vinckenbosch","sequence":"first","affiliation":[{"name":"Faculty of Psychology and Neuroscience Maastricht University  Maastricht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerryll","family":"Asin","sequence":"additional","affiliation":[{"name":"Center for Sleep Medicine Amphia  Breda Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaas","family":"de Vries","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences Department of Otorhinolaryngology Head and Neck Surgery Antwerp University Hospital  Antwerp Belgium"},{"name":"OLVG  Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty E.","family":"Vonk","sequence":"additional","affiliation":[{"name":"OLVG  Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E. H. M.","family":"Donjacour","sequence":"additional","affiliation":[{"name":"Sleep\u2013Wake Centre SEIN  Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert Jan","family":"Lammers","sequence":"additional","affiliation":[{"name":"Sleep\u2013Wake Centre SEIN  Netherlands"},{"name":"Department of Neurology Leiden University Medical Center  Leiden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Overeem","sequence":"additional","affiliation":[{"name":"Sleep Medicine Center Kempenhaeghe  Heeze Netherlands"},{"name":"Department of Electrical Engineering Biomedical Diagnostics Group Eindhoven University of Technology  Eindhoven Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hennie","family":"Janssen","sequence":"additional","affiliation":[{"name":"Sleep Medicine Center Kempenhaeghe  Heeze Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Wang","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals  Palo Alto California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals  Palo Alto California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence P.","family":"Carter","sequence":"additional","affiliation":[{"name":"Alexza Pharmaceuticals Inc  Mountain View California USA"},{"name":"University of Arkansas for Medical Sciences  Little Rock Arkansas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals  Palo Alto California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"Vermeeren","sequence":"additional","affiliation":[{"name":"Faculty of Psychology and Neuroscience Maastricht University  Maastricht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[{"name":"Faculty of Psychology and Neuroscience Maastricht University  Maastricht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157318"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(19)30198\u20105"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2015.05.013"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl\u20102013\u2010203796"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/mcp.0000000000000324"},{"key":"e_1_2_9_8_1","volume-title":"Modafinil \u2010 Article 31 referral \u2010 Annex I, II, III, IV","author":"European Medicines Agency","year":"2011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5834"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12039"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010016\u20104519\u2010z"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.2662"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5384"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890\u2010019\u20101041\u20101"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz220"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1652271"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2007.01.009"},{"key":"e_1_2_9_18_1","unstructured":"Nuvigil [package insert]. (2018).Teva Pharmaceuticals."},{"issue":"5","key":"e_1_2_9_19_1","first-page":"391","article-title":"Excessive daytime sleepiness","volume":"79","author":"Pagel J. F.","year":"2009","journal-title":"American Family Physician"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00016808"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.04.007"},{"key":"e_1_2_9_22_1","unstructured":"Provigil [package insert]. (2018). Teva Pharmaceuticals."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.01.006"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360\u20100443.2006.01566.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5968"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806\u20101100OC"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/nss.s91928"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2006.04.012"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7624"},{"key":"e_1_2_9_30_1","unstructured":"Sunosi\u2122 (solriamfetol) tablets Prescribing Information. (2021). Jazz Pharmaceuticals Inc."},{"key":"e_1_2_9_31_1","unstructured":"Sunosi\u2122 (solriamfetol) tablets Summary of Product Characteristics. (2020). Jazz Pharmaceuticals Ireland Ltd."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00225113"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.27662"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082946"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s19639"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2011.09.003"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2778"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202002\u2010136OC"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz067.599"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200908\u20101307OC"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2016.02.008"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hup.2845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:37:13Z","timestamp":1692704233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/hup.2845"],"URL":"https:\/\/doi.org\/10.1002\/hup.2845","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"2021-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2845"}}